Complex bronchiectasis represents a heterogeneous group of severe, advanced, or refractory cases of bronchiectasis requiring multidisciplinary specialty care beyond standard outpatient management. Indications for multidisciplinary referral include frequent exacerbations (>3 per year despite optimization), chronic infection with difficult organisms (Pseudomonas aeruginosa, Mycobacterium avium complex, multidrug-resistant organisms, Aspergillus), severe lung function decline (FEV1 <50% predicted), bilateral extensive disease, recurrent hospitalization, hemoptysis, suspected immunodeficiency, suboptimal response to standard therapy, candidacy for surgery or transplantation, and significant impact on quality of life and employment.
The multidisciplinary team typically includes specialized pulmonologist (bronchiectasis center), infectious disease specialist (for resistant infection management), clinical microbiologist (specialized cultures and resistance testing), respiratory physiotherapist (airway clearance technique optimization), dietitian (BMI maintenance, nutritional supplementation), thoracic surgeon (for localized disease, lobectomy/pneumonectomy candidates), pulmonary transplantation specialist (for end-stage disease), psychosocial support, and patient education team.
Comprehensive evaluation includes detailed etiology workup (genetic testing for cystic fibrosis CFTR mutations, primary ciliary dyskinesia, immunoglobulins quantification, IgG subclasses, vaccine antibody response, alpha-1 antitrypsin, autoimmune markers, ABPA evaluation, mycobacterial cultures), high-resolution CT for disease distribution and complications, lung function with serial monitoring, sputum surveillance with sensitivity testing, and functional assessment with 6-minute walk test, quality of life questionnaires. Management strategies include long-term inhaled antibiotic therapy (tobramycin, colistin, ciprofloxacin) for chronic Pseudomonas suppression, rotational oral antibiotic prophylaxis (azithromycin three times weekly for immunomodulation in frequent exacerbators), aggressive eradication of newly acquired Pseudomonas, individualized exacerbation antibiotic strategies, intensive airway clearance with multiple modalities (high-frequency chest wall oscillation vest, positive expiratory pressure, autogenic drainage), bronchodilators when responsive, hypertonic saline nebulization, mucolytic therapy, vaccination optimization (pneumococcal, influenza, COVID), pulmonary rehabilitation, surgical resection for localized disease causing recurrent infection or hemoptysis, and lung transplantation evaluation for end-stage disease.